+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bupivacaine Hydrochloride for Injection Market by Route Of Administration, Concentration, Application, End User - Global Forecast to 2030- Product Image
Bupivacaine Hydrochloride for Injection Market by Route Of Administration, Concentration, Application, End User - Global Forecast to 2030- Product Image
Sale

Bupivacaine Hydrochloride for Injection Market by Route Of Administration, Concentration, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080331
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Unveiling the Clinical Potential of Bupivacaine Hydrochloride

Bupivacaine hydrochloride for injection has emerged as an indispensable agent in regional anesthesia and acute pain management across diverse clinical settings. Its long-acting anesthetic profile, combined with a favorable safety margin, positions it as a cornerstone in labor and delivery suites, postoperative care units, and outpatient surgical centers. Over the past decade, incremental refinements in formulation and administration techniques have broadened its therapeutic applications and reinforced its clinical value proposition.

In response to evolving patient needs and healthcare paradigms, this executive summary distills the essential market dynamics shaping the bupivacaine hydrochloride landscape. It provides decision-makers with an integrated view of regulatory developments, segmentation insights, regional variances, competitive forces, and actionable recommendations. By synthesizing critical factors without numerical market sizing, this analysis equips stakeholders with the knowledge to optimize product positioning, streamline supply chain operations, and drive sustainable growth in a highly regulated environment.

Navigating Shifts Reshaping the Bupivacaine Landscape

As the healthcare sector transitions toward minimally invasive procedures and enhanced patient-centric care, bupivacaine hydrochloride has benefited from several transformative shifts. Technological advancements in drug delivery systems, such as programmable infusion pumps and extended-release formulations, have amplified its clinical versatility. At the same time, a surge in ambulatory surgery centers has accelerated demand for reliable long-duration anesthesia that minimizes postoperative recovery times.

Further, healthcare providers are embracing multimodal pain management protocols to reduce opioid reliance, thereby elevating the role of long-acting local anesthetics. Regulatory agencies have also streamlined pathways for generic approvals, intensifying competition and driving innovation in cost-effective manufacturing. Against this backdrop, the market has witnessed a convergence of precision medicine principles with digital health monitoring, enabling real-time assessment of analgesic efficacy and patient safety.

These collective shifts underscore a broader trend toward integrated perioperative care models, where bupivacaine hydrochloride serves as a key enabler of enhanced clinical outcomes and operational efficiencies.

Assessing the Ripple Effects of 2025 Tariff Changes in the US

The introduction of new tariff measures by the United States in 2025 is poised to reshape the cost structure and supply chain dynamics of bupivacaine hydrochloride. Heightened duties on key active pharmaceutical ingredients imported from overseas manufacturing hubs have exerted upward pressure on raw material costs. In turn, pharmaceutical producers are reassessing sourcing strategies and forging partnerships with domestic suppliers to mitigate exposure to international trade fluctuations.

These tariff-induced cost escalations have prompted downstream stakeholders, including hospitals and surgery centers, to scrutinize procurement contracts and explore bundled purchasing arrangements. Some manufacturers have responded by optimizing their production footprints to maximize economies of scale, while others are investing in vertically integrated supply capabilities. Simultaneously, parallel efforts to diversify manufacturing sites and secure alternative API vendors are underway to reinforce supply security.

While the full ramifications of these tariff adjustments will unfold over the coming years, early indicators suggest a strategic redistribution of manufacturing assets and a recalibration of pricing models. Stakeholders who proactively adapt their sourcing and pricing strategies stand to maintain competitive advantage amid this new trade environment.

Insights from Multidimensional Segmentation Analysis

The analysis of market segmentation reveals nuanced adoption patterns that vary by route of administration, concentration, application, and end user. In the context of administration routes, epidural injections-particularly those employed in labor and delivery as well as postoperative pain management-continue to command significant clinical preference. Local infiltration techniques have gained traction in dental surgery scenarios and the management of surgical wounds, while peripheral nerve block approaches, spanning both continuous catheter infusions and single shot interventions, are increasingly integrated into orthopedic and outpatient surgical protocols.

Concentration gradients of 0.25 percent, 0.5 percent, and 0.75 percent formulations cater to distinct analgesic depth requirements. Lower concentrations find favor in pediatric and dental procedures where sensory blockade must be balanced against motor function preservation. Midrange formulations are widely utilized in general surgery and obstetric settings, while the highest concentration options address the most intensive pain control demands encountered in major orthopedic and trauma-related interventions.

Application-specific insights further underscore the versatility of bupivacaine hydrochloride. Dental procedures benefit from localized anesthesia with rapid onset, whereas general surgery protocols leverage prolonged analgesia to facilitate early mobilization. Obstetrics demands formulations that ensure maternal comfort without compromising neonatal safety, and orthopedic surgery routines require sustained nerve blockade to optimize rehabilitation outcomes.

Finally, end users such as ambulatory surgery centers prioritize formulations that align with high patient throughput, clinics emphasize cost-effective dosing regimens, and hospitals focus on broad-spectrum applications that streamline inventory management while meeting rigorous safety standards.

Regional Nuances Driving Market Dynamics

Regional analysis illuminates how distinct economic, regulatory, and healthcare delivery frameworks shape the bupivacaine hydrochloride market. In the Americas, robust reimbursement policies and extensive surgical volumes drive steady demand, while innovation in outpatient care models amplifies the role of long-acting anesthetics. North American healthcare systems are also early adopters of advanced delivery technologies, bolstering market growth.

In Europe, Middle East, and Africa, regulatory harmonization efforts within the European Union facilitate cross-border product registrations, although disparate approval timelines in emerging markets create variability in market entry strategies. Healthcare infrastructure modernization in select Middle Eastern and African nations is generating new opportunities, particularly for ambulatory surgery and minimally invasive procedural growth.

The Asia-Pacific region represents a high-growth frontier, where expanding hospital networks, rising surgical rates, and increasing healthcare expenditure converge. Nations such as China and India are accelerating local API production capabilities, while Southeast Asian markets prioritize partnerships with established pharmaceutical firms to enhance access to premium formulations. Across these regions, demographic shifts and rising chronic disease burdens are poised to sustain long-term demand for effective pain management solutions.

Competitive Forces Shaping Bupivacaine Offerings

The competitive ecosystem for bupivacaine hydrochloride is characterized by both global pharmaceutical leaders and agile generic manufacturers. Established multinational companies leverage extensive distribution networks and strategic alliances with healthcare providers to maintain strong market presence. Their portfolios often include proprietary formulations that combine bupivacaine with adjunctive agents to extend analgesic duration and improve postoperative comfort.

Concurrently, specialized generics firms are concentrating on cost leadership and rapid product launches, capitalizing on patent expirations and simplified regulatory pathways to capture volume-driven segments. Partnerships between branded and generic players have also emerged, with licensing agreements and co-marketing arrangements enabling faster market access and shared risk exposure.

Innovation in delivery systems, such as liposomal encapsulation and syringe-based programmable pumps, further distinguishes leading competitors. Those companies that integrate formulation expertise with advanced administration technologies are gaining traction among high-volume end users that prioritize both clinical performance and operational efficiency.

Strategic Imperatives for Market Leadership

To thrive in an increasingly sophisticated market environment, industry leaders must prioritize strategic investments and collaborative initiatives. Strengthening supply chain resilience through diversification of API sources will mitigate exposure to trade policy fluctuations. At the same time, pursuing regulatory alignment and expedited approvals in growth markets can unlock new revenue streams and reinforce competitive positioning.

Innovators should focus on next-generation delivery platforms that enhance safety and patient comfort, such as programmable pump interfaces and sustained-release formulations. Collaborating with healthcare providers to design real-world evidence studies will further validate the clinical and economic benefits of these advanced solutions.

Moreover, targeted expansion into underpenetrated segments-especially emerging Asia-Pacific markets and high-volume outpatient facilities-can drive incremental adoption. Integrating digital monitoring tools to capture analgesic efficacy metrics will differentiate offerings and foster value-based purchasing arrangements with payers and provider networks.

Rigorous Methodological Framework Underpinning the Study

This study employed a rigorous mixed-methods approach, combining extensive secondary research with primary data collection. An initial desk review encompassed regulatory filings, clinical trial registries, governmental health reports, and peer-reviewed publications to establish a foundational understanding of the bupivacaine hydrochloride landscape.

Building on this foundation, qualitative interviews were conducted with key opinion leaders, purchasing decision-makers, and formulation specialists to capture firsthand insights on product performance, adoption barriers, and emerging trends. Quantitative validation was achieved through structured surveys targeting pharmacists, anesthesiologists, and procurement managers, ensuring consistency across diverse stakeholder perspectives.

Data triangulation processes were applied to reconcile findings from multiple sources, while peer review by external subject matter experts ensured methodological integrity and the elimination of bias. The resulting framework provides a transparent and defensible basis for the segmentation, regional analysis, and competitive assessment presented in this report.

Synthesizing Key Takeaways and Future Perspectives

In summary, bupivacaine hydrochloride for injection stands at the intersection of innovation in anesthetic delivery and evolving healthcare demands. Segmentation analysis reveals differentiated use cases across administration routes, concentrations, clinical applications, and care settings. Regional insights highlight established markets in the Americas and Europe, while high-growth trajectories in Asia-Pacific signal future expansion opportunities.

Competitive dynamics are shaped by branded leaders advancing novel formulations and generics firms driving accessibility through cost-effective offerings. Emerging trade policies necessitate proactive supply chain strategies, and technological breakthroughs in delivery systems present avenues for differentiation. Taken together, these insights form a holistic perspective on the forces influencing market evolution and inform strategic decision-making for industry stakeholders.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Epidural
      • Labor And Delivery
      • Postoperative Pain
    • Local Infiltration
      • Dental Surgery
      • Surgical Wound
    • Peripheral Nerve Block
      • Continuous Catheter Block
      • Single Shot Block
  • Concentration
    • 0.25%
    • 0.5%
    • 0.75%
  • Application
    • Dental Procedures
    • General Surgery
    • Obstetrics
    • Orthopedic Surgery
  • End User
    • Ambulatory Surgery Centers
    • Clinics
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Fresenius Kabi AG
  • AstraZeneca PLC
  • Hikma Pharmaceuticals PLC
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bupivacaine Hydrochloride for Injection Market, by Route Of Administration
8.1. Introduction
8.2. Epidural
8.2.1. Labor And Delivery
8.2.2. Postoperative Pain
8.3. Local Infiltration
8.3.1. Dental Surgery
8.3.2. Surgical Wound
8.4. Peripheral Nerve Block
8.4.1. Continuous Catheter Block
8.4.2. Single Shot Block
9. Bupivacaine Hydrochloride for Injection Market, by Concentration
9.1. Introduction
9.2. 0.25%
9.3. 0.5%
9.4. 0.75%
10. Bupivacaine Hydrochloride for Injection Market, by Application
10.1. Introduction
10.2. Dental Procedures
10.3. General Surgery
10.4. Obstetrics
10.5. Orthopedic Surgery
11. Bupivacaine Hydrochloride for Injection Market, by End User
11.1. Introduction
11.2. Ambulatory Surgery Centers
11.3. Clinics
11.4. Hospitals
12. Americas Bupivacaine Hydrochloride for Injection Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Bupivacaine Hydrochloride for Injection Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Bupivacaine Hydrochloride for Injection Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Fresenius Kabi AG
15.3.3. AstraZeneca PLC
15.3.4. Hikma Pharmaceuticals PLC
15.3.5. Baxter International Inc.
15.3.6. B. Braun Melsungen AG
15.3.7. Sandoz International GmbH
15.3.8. Teva Pharmaceutical Industries Ltd.
15.3.9. Viatris Inc.
15.3.10. Sun Pharmaceutical Industries Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET MULTI-CURRENCY
FIGURE 2. BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET MULTI-LANGUAGE
FIGURE 3. BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LABOR AND DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY DENTAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY SURGICAL WOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONTINUOUS CATHETER BLOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY SINGLE SHOT BLOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY 0.25%, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY 0.5%, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY 0.75%, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY DENTAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY OBSTETRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 50. CANADA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 52. CANADA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 53. CANADA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. MEXICO BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. GERMANY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 94. GERMANY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 95. GERMANY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 96. GERMANY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. FRANCE BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. FRANCE BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 100. FRANCE BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 101. FRANCE BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 102. FRANCE BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 103. FRANCE BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. FRANCE BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. ITALY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. ITALY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 114. ITALY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 115. ITALY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 116. ITALY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 117. ITALY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. ITALY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. SPAIN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SPAIN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 121. SPAIN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 122. SPAIN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 123. SPAIN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 124. SPAIN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. SPAIN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. DENMARK BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. DENMARK BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 149. DENMARK BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 150. DENMARK BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 151. DENMARK BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 152. DENMARK BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. QATAR BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. QATAR BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 163. QATAR BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 164. QATAR BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 165. QATAR BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 166. QATAR BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. QATAR BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FINLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. FINLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. EGYPT BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. EGYPT BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 191. EGYPT BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 192. EGYPT BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 193. EGYPT BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 194. EGYPT BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. EGYPT BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. TURKEY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. TURKEY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 198. TURKEY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 199. TURKEY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 200. TURKEY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 201. TURKEY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. TURKEY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. NORWAY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. POLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. POLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 219. POLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 221. POLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 222. POLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. CHINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 241. CHINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 242. CHINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 243. CHINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 244. CHINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. CHINA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. INDIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. INDIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 248. INDIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 249. INDIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 250. INDIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 251. INDIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 256. JAPAN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY EPIDURAL, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY LOCAL INFILTRATION, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY PERIPHERAL NERVE BLOCK, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY CONCENTRATION, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA BUPIVACAINE HYDROCHLORIDE FOR INJECTION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. THAILAND BUPIVACAINE

Companies Mentioned

The companies profiled in this Bupivacaine Hydrochloride for Injection market report include:
  • Pfizer Inc.
  • Fresenius Kabi AG
  • AstraZeneca PLC
  • Hikma Pharmaceuticals PLC
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bupivacaine Liposome Injection Market by End Use, Indication, Application, Distribution Channel, Patient Type, Product Type, Packaging - Global Forecast to 2030 - Product Image

Bupivacaine Liposome Injection Market by End Use, Indication, Application, Distribution Channel, Patient Type, Product Type, Packaging - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Bupivacaine Hydrochloride (CAS 18010-40-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Bupivacaine Hydrochloride (CAS 18010-40-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Ropivacaine Hydrochloride & Sodium Chloride Injection Market by Application Type, Formulation, End User, Dosage Strength, Distribution Channel - Global Forecast to 2030 - Product Image

Ropivacaine Hydrochloride & Sodium Chloride Injection Market by Application Type, Formulation, End User, Dosage Strength, Distribution Channel - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Dental Anesthetics Market by Drug Type (Lidocaine, Mepivacaine, Articaine, Bupivacaine, Mepivacaine, Prilocaine), Route of Administration (Topical, Injectable, Syringes, Needles), End User (Hospitals, Clinics, Others), Region - Global Forecast to 2030 - Product Image

Dental Anesthetics Market by Drug Type (Lidocaine, Mepivacaine, Articaine, Bupivacaine, Mepivacaine, Prilocaine), Route of Administration (Topical, Injectable, Syringes, Needles), End User (Hospitals, Clinics, Others), Region - Global Forecast to 2030

  • Report
  • 245 Pages
  • Global
From
Local Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Bupivacaine, Ropivacaine, Lidocaine), By Application (Injectable, Surface Anesthetic), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Local Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Bupivacaine, Ropivacaine, Lidocaine), By Application (Injectable, Surface Anesthetic), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.